NCT05973370View on ClinicalTrials.gov

Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

May 30, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Placebo

Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

DRUG

Ursodeoxycholic acid (UDCA) 500 mg

All subjects will receive Ursodeoxycholic acid (UDCA) administered at 500 mg/day for 24 weeks as an addon treatment to the current DMARDs treatments for rheumatoid arthritis.

Trial Locations (1)

Unknown

Menoufia University Hospital, Shibīn al Kawm

All Listed Sponsors
lead

Tanta University

OTHER

NCT05973370 - Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter